Roger Zoorob

Has grant

Richard M. Kleberg, Sr. Professor and Chair

Baylor College of Medicine
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Roger Zoorob is the Richard M. Kleberg, Sr. Professor and Chair at Baylor College of Medicine in the United States. His research areas focus on antibiotic resistance, primary care patient behaviors regarding antibiotic use, and the impact of healthcare worker experiences during the COVID-19 pandemic. Dr. Zoorob has also explored cancer trends and healthcare disparities, particularly in relation to smoking cessation and screening programs.

Recent Grants

Grant: Close

Come Home Houston

Open Date: 2020-04-01

Close Date: 2025-04-01

Grant: Close

Bringing Alcohol and Other Drug Research to Primary Care

Open Date: 2020-04-01

Close Date: 2024-03-01

Grant: Close

ringing Alcohol and Other Drug Research to Primary Care

Open Date: 2020-04-01

Close Date: 2024-03-01

Grant: Close

AWARE-HOUSTON/MHAT

Open Date: 2020-04-01

Close Date: 2023-04-01

Grant: Close

Project REACH: Improve HIV and Hepatitis C prevention, screening and access to recovery services for individuals with a substance use disorder and/or co-occurring substance use and mental health disorders

Open Date: 2018-09-01

Close Date: 2023-09-01

Articles (13)

Background Risk factors for ciprofloxacin or MDR in primary care urine specimens are not well defined. Objectives We created a primary care-specific antibiogram for Escherichia coli isolates from cases with complicated and uncomplicated urinary tract infection (UTI) and evaluated risk factors for ciprofloxacin, trimethoprim/sulfamethoxazole and MDR among Enterobacterales. Methods We conducted a cross-sectional study to determine resistance and risk factors by collecting urine cultures from all patients (≥18 years) presenting with provider-suspected UTI at two primary care, safety-net clinics in Houston, TX, USA between November 2018 and March 2020. Results Among 1262 cultures, 308 cultures grew 339 uropathogens. Patients with Enterobacterales (n = 199) were mostly female (93.5%) with a mean age of 48.5 years. E. coli was the predominant uropathogen isolated (n = 187/339; 55%) and had elevated trimethoprim/sulfamethoxazole (43.6%) and ciprofloxacin (29.5%) resistance, low nitrofurantoin (1.8%) resistance, and no fosfomycin resistance. Among E. coli, 10.6% were ESBL positive and 24.9% had MDR. Birth outside the U.S.A., prior (2 year) trimethoprim/sulfamethoxazole resistance, and diabetes mellitus were associated with trimethoprim/sulfamethoxazole resistance. Prior (60 day) fluoroquinolone use, prior ciprofloxacin resistance and both diabetes mellitus and hypertension were strongly associated with ciprofloxacin resistance. Prior fluoroquinolone use and a history of resistance to any studied antibiotic were associated with MDR, while pregnancy was protective. Conclusions We found elevated resistance to UTI-relevant antimicrobials and novel factors associated with resistance; these data can be incorporated into clinical decision tools to improve organism and drug concordance.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Barbara Trautner

Baylor College of Medicine

UNITED STATES
View details

Maria Carmenza Mejia

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Jacqueline Hirth

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Larissa Grigoryan

Baylor College of Medicine

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.